Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Steve Cohen Discloses 5.0% Stake In Ironwood Pharmaceuticals Inc. (IRWD)

On the surface, it seems that Ironwood Pharmaceuticals is doing great, as the net sales generated from its linaclotide on the U.S. market amounted to $112.1 million in the second quarter, marking a 79% increase year-over-year. However, the company’s sales are expected to be struck by Synergy Pharmaceuticals (NASDAQ:SGYP)’s competing drug that continues to do extremely well in its clinical trials. Just recently, Synergy reported positive data for its plecanatide in a Phase III study of 1,346 patients with chronic idiopathic constipation (CIC). The results of the study have shown similar top-line efficacy to the results seen in Ironwood’s linaclotide. Moreover, tolerability data seems to indicate that plecanatide outperforms Ironwood’s product. Synergy Pharmaceuticals is anticipated to announce the results for a second Phase III CIC trial during the third quarter, and intends to file a New Drug Application (NDA) for plecanatide by the end of this year, which means that the product could be brought to the market by the end of next year. Ultimately, it is highly probable that Ironwood’s market share will suffer substantially should Synergy’s plecanatide get FDA approval next year.

Nevertheless, Ironwood’s competitive advantage lies in the fact that its product has started commercializing well ahead of Synergy’s product. Ironwood Pharmaceutical has revealed that more than 510,000 linaclotide prescriptions were filled in the second quarter, up by 56% year-over-year. Even more to that, the company intends to file for China Food and Drug Administration (CFDA) approval to market lenaclotide there at the beginning of 2016, after top-line data has demonstrated that the product met all primary and secondary endpoints in a Phase III clinical trial of adults with irritable bowel syndrome with constipation (IBS-C) conducted in China. Therefore, linaclotide might be the first-of-its-kind prescription in China for adults with IBS-C, which will surely unlock a very prosperous revenue stream for the company.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.